As Principal Investigator (PI) or Project Leader
10/1/2016-9/31/2018, PharmaMar S.A. Characterization of Aplidin® (plitidepsin) effects on multiple myeloma (MM)-induced bone disease. Role: PI
9/30/2014-8/31/2019, NIH-NCCAM R01-AT008754 and O2S1-AT008754. Berries and bone. Role: PI of subcontract IU-Purdue University; PI C Weaver
10/1/2013-9/30/2017, VA I01 BX002104 Merit Award. Osteocyte control of bone remodeling through the PTH receptor. Role: PI
09/2011-08/2017, NIH R01 AR059357. FAK/Pyk2 signaling pathway and bone formation. Role: PI
04/2017-03/2022, NIH R01 CA209882. Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma. Role MPI with GD Roodman
06/2017, NSF Support for Junior Investigators at the ORS Musculoskeletal Biology Workshop at Sun Valley, Idaho. Role: PI
As co-Investigator, Mentor or Collaborator
12/1/15-11/30/2020, NIH R01 AR068332. CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis. Role: Co-Investigator. PI: U Sankar.
4/1/2015-3/31/2020, NIH R01AR067210. Osteocyte apoptosis and regulation of bone resorption with aging. Role: Co-Investigator. PI: LI Plotkin
4/1/2013-3/31/2018, NIH R01. Control of FGF23 bioactivity via circulating alphaKlotho. Role: Co-Investigator. PI.: KE White
7/1/2016-6/30/2017, AAOF – American Association of Orthodontics Foundation. The effect of intermittent PTH on mandibular condylar cartilage. Role: co-Investigator. PI: A Utreja
12/1/2011-11/31/2020, VA I01 BX001478 Merit Award. Harnessing the anabolic potential of Wnt signaling to improve bone health. Role Co-I; PI: AR Robling
Sato AY, Tu X, McAndrews KA, Plotkin LI, Bellido T. Prevention of Glucocorticoid Induced-Apoptosis of Osteoblasts and Osteocytes by Protecting against Endoplasmic Reticulum (ER) Stress in vitro and in vivo in Female Mice. Bone, 73: 60-68, 2015
Tu X,* Delgado-Calle J,* Condon K, Maycas M, Zhang H, Carlesso N, Taketo MM, Burr D, Plotkin LI, Bellido T. Osteocytes mediate the anabolic actions of canonical Wnt/βcatenin signaling in bone. Proceedings of National Academy of Sciences, 112 (5) E478-E486, 2015. [Epub ahead of print] (Highlighted in Nature Reviews Endocrinology; and in Nature Reviews Rheumatology) *Both first authors
Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch signaling and osteocyte-derived factors drive tumor cell proliferation and bone destruction in multiple myeloma. Cancer Research, 2016, DOI: 10.1158/0008-5472.CAN-15-1703.
Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T. Protection from Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. Journal of Bone and Mineral Research, 31(10): 1791-1802, 2016
Pellegrini GG, Morales CC, Wallace TC, Plotkin LI, Bellido T. Avenanthramides prevent osteoblast and osteocyte apoptosis and induce osteoclast apoptosis in an Nrf2-independent manner. Nutrients, 2016 8, 423-427; doi:10.3390/nu8070423
Maycas M, McAndrews KA, Sato AY, Pellegrini GG, Brown DM, Allen MR, Plotkin LI, Gortazar AR, Esbrit P, Bellido T. PTHrP-Derived Peptides Restore Bone Mass and Strength in Diabetic Mice: Additive Effect of Mechanical Loading. Journal of Bone and Mineral Research doi 0.1002/jbmr.3007, 2016.
Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini G, Kuhlenschmidt K, Olivos N, Robling A, Peacock M, Plotkin LI, Bellido T. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor. Journal of Bone and Mineral Research doi: 10.1002/jbmr.3011, 2016.
Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI, Bellido T. Glucocorticois induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology (in press)
Pellegrini GG, Cregor M, McAndrews K, Morales CC, Doyle McCabe L, McCabe GP, Peacock M, Burr D, Weaver C, Bellido T. Nrf2 regulates mass accrual and the antioxidant endogenous response in bone differently depending on the sex and age. PLoS ONE (in press)
Delgado-Calle J, Anderson J, Cregor M, Condon K, Kuhstoss S, Plotkin LI, Bellido T,* and Roodman GD*. Genetic Deletion of Sost or Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-induced Bone Disease without Affecting Tumor Growth. Leukemia (in press) * Corresponding authors
Additional Research Team Members
Other research team members include Amy Y. Sato, PhD (Postdoctoral fellow), Emily Atkinson (Graduate student), Kevin McAndrews, MS (Research Technician), Melony Cregor (Research Technician), and Jessica H. Nelson (Research Technician)